Dr. Black Discusses Immunotherapy Biomarkers in Bladder Cancer

Peter Black, MD
Published: Monday, Aug 07, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Investigators are actively investigating biomarkers in bladder cancer. Black says that only about 20% to 25% of patients achieve an objective response to immunotherapy. Moreover, the drugs are expensive and potentially toxic, so it is important to select the right types of patients for them.

The easiest biomarker is PD-L1 immunohistochemistry, but currently has no utility in patients with bladder cancer, Black says.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Investigators are actively investigating biomarkers in bladder cancer. Black says that only about 20% to 25% of patients achieve an objective response to immunotherapy. Moreover, the drugs are expensive and potentially toxic, so it is important to select the right types of patients for them.

The easiest biomarker is PD-L1 immunohistochemistry, but currently has no utility in patients with bladder cancer, Black says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x